Andy Lane is the Commercial Director at The Native Antigen Company. As the number of cases of COVID-19 began to climb in late 2019, labs began collecting and sequencing patient isolates. Within weeks, the first draft sequence of the SARS-CoV-2 genome was published, opening the gates for a wave of early research (1). At the time, one of the major questions surrounding SARS-CoV-2 was its natural mutation rate. It has long been understood that viral genomes naturally mutate over time.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Andy Lane
Collaborative approach key to UK CCUS
Welcome to the PE Media Network In 2021 Petroleum Economist is joined by Hydrogen Economist and Transition Economist to form the only genuinely comprehensive intelligence service covering the global energy industry To celebrate the launch of our two new channels we are making Hydrogen Economist and Transition Economist free to everyone for a limited time only
The Pandemic Diaries
Mike Grippo, Senior Vice President, Strategy & Corporate Development at Catalent Pharma Solutions COVID-19 is one of the greatest humanitarian challenges of our lifetime. I see companies acting with great resolve and resilience, addressing the immediate challenges of COVID-19, and what it represents to their workforce, customers, partners and patients. I see “unsung” heroes – people who persevere and perform in important but less visible jobs – making a significant difference.
The Pandemic Diaries
Mike Grippo, Senior Vice President, Strategy & Corporate Development at Catalent Pharma Solutions COVID-19 is one of the greatest humanitarian challenges of our lifetime. I see companies acting with great resolve and resilience, addressing the immediate challenges of COVID-19, and what it represents to their workforce, customers, partners and patients. I see “unsung” heroes – people who persevere and perform in important but less visible jobs – making a significant difference.
The Bumpy Road to a Cytomegalovirus Vaccine
To say that cytomegalovirus (CMV) is common would be an understatement. The virus, which belongs to the Herpesviridae family, infects the majority of people over the course of their lifetime, making it one of the most ubiquitous human pathogens in the world (1, 2). And yet general awareness of CMV and its impact on human health (particularly the risk of congenital infection) is relatively poor.
Blog alert on the ease of cyber attacks on ships was pure scaremongering - The Loadstar
Last month a much-reported blog – included in The Loadstar – claimed “sinking ships [via hacking], really wouldn’t take much”. Not only was that overly dramatic and not helpful for safety of life at sea, but it was irresponsible as well as being fundamentally flawed: the input assumptions were totally incorrect.
'Near-shoring shift' a more serious threat than bigger ships/smaller loads paradox - The Loadstar
An opinion piece last week in The Loadstar responded to the likelihood that a series of ultra-large container vessels (ULCVs, or more recently dubbed by Alphaliner Megamaxes) are now under construction in China and South Korea. And it set it beside another news story which predicted the era of the full-container-load (FCL) was coming to an end, and posed the perfectly reasonable question: how will carriers overcome the paradox of building bigger ships for smaller consignments?
July 2016 Comments & Letters | News | American Shipper
July 2016 Comments & Letters By Gary Ferrulli, Edward M. Korleski, Ed Bastian and Andy Lane |Tuesday, June 28, 2016 Shippers should worry about fewer liner carriers Your June issue editorial (“Shippers should be outspoken about liner shakeout,” page 48) on what happens to shippers is a great point, but leaves out some important facts and conclusions. This will mark the sixth straight year that the container industry will lose money.
Towers Watson, Willis merger to combine strengths
Towers Watson & Co., with $2.2 trillion in assets under advisement, is expected to dominate the investment consulting arm of the business after it combines with Willis Group Holdings PLC, sources said. But those sources also said they expect the merger to be the end of Towers Watson's status as a serious bidder for Russell Investments. The merger, expected to close by the end of the year, will create a new company, Willis Towers Watson PLC.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Andy
Contact Andy, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack